Siemens Healthineers received clearance for its Dimension Exl High-Sensitivity Troponin I Assay used to diagnose acute myocardial infarction.
BioMérieux has increased its stake in Chinese immunoassay developer Hybiome Biomedical Engineering from 54 percent to 67 percent.
In the quarter the firm acquired food and beverage testing firm Invisible Sentinel and partnered with Baxter International to develop acute kidney injury biomarkers.
Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
Beckman Coulter got regulatory clearance for three in vitro diagnostic products, including its DxH 520 hematology analyzer for low-volume clinical labs.
Value-Dx is being spearheaded by six in vitro diagnostic firms and 20 non-industry partners and will be funded with with €14 million over four years.
The firms will focus on developing and implementing biomarker-based immunoassay diagnostics for kidney injury.
Since moving to rapid molecular testing, the lab has doubled its billable test volume, largely through increasing clients for its outreach lab services.
The firm also reported full-year 2018 sales of €2.42 billion, a year-over-year increase of 6 percent on a reported basis, or 10 percent organically.